Brief: FDA Reissues Lumiradx Fast Lab Solutions' Eua For Sars Cov-2 Rna Star Complete Molecular Reagents To Allow High Throughput And Asymptomatic Testing Solutions
01/12/2021 13:29
Dec 1 (Reuters) - LumiraDx Ltd LMDX.O :
* FDA REISSUES LUMIRADX FAST LAB SOLUTIONS' EUA FOR SARS
COV-2 RNA
STAR COMPLETE MOLECULAR REAGENTS TO ALLOW HIGH THROUGHPUT AND
ASYMPTOMATIC TESTING SOLUTIONS
Source text for Eikon: ID:nPn4jmmjca
Further company coverage: LMDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LumiraDx
See all newsBrief: LumiraDx Announces Its Securities Will Be Suspended From Trading On Nasdaq At The Open Of Business On January 9Th
Roche to buy part of LumiraDx diagnostics platform for $295 million
Brief: LumiraDx- Under Terms Of Certain Loan Agreement, Dated March 23, 2021, The Waiver Period Has Expired As Of Today
Brief: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
Brief: Willard L. Umphrey Reports 10.31% Stake In Lumiradx Limited As Of Dec 22- SEC Filing